# AMG 319 Lymphoid Malignancy FIH

> **NCT01300026** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 28 (actual)

## Conditions studied

- Cancer
- Chronic Lymphocytic Leukemia
- Diffuse Large Cell Lymphoma
- Hematologic Malignancies
- Hematology
- Leukemia
- Low Grade Lymphoma
- Lymphoma
- Mantle Cell Lymphoma
- Non-Hodgkin's Lymphoma
- Oncology
- Oncology Patients
- T Cell Lymphoma
- Tumors

## Interventions

- **DRUG:** AMG 319

## Key facts

- **NCT ID:** NCT01300026
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2013-10
- **Final completion:** 2016-12
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2017-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300026, "AMG 319 Lymphoid Malignancy FIH". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01300026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*